Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

EBV-Positive DLBCL, Nos Clinical Trial

Official title:
A Phase II, Prospective, Multi-center Study of Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS

Status Recruiting

Clinical Trial Summary

The prognosis of EBV+ DLBCL is dismal. Previous study showed that high level of PD-L1 expression in EBV+ DLBCL. The investigators therefore design this phase II study to investigate the safety and efficacy of sintilimab (an anti-PD-1 antibody) in combination with R-CHOP in patients with treatment-naive EBV+ DLBCL.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04181489
Study type	Interventional
Source	The First Affiliated Hospital with Nanjing Medical University
Contact	yi xia, M.D., Ph.D.
Phone	025-68306034
Email	cynthia0311@163.com
Status	Recruiting
Phase	Phase 2
Start date	January 1, 2019
Completion date	December 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05011058` - An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas	Phase 2
Recruiting	`NCT04796857` - Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL	Phase 1/Phase 2
Recruiting	`NCT05583149` - Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas	Phase 2
Recruiting	`NCT04476459` - Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL	Phase 1/Phase 2
Recruiting	`NCT04705129` - Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL	Phase 2
Recruiting	`NCT04058470` - Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05544019` - Study of SGR-1505 in Mature B-Cell Neoplasms	Phase 1